RT Journal Article
SR Electronic
T1 Gait and Balance Function Improves After 10 Weeks of Using a Wearable Sensory Neuroprosthesis in Persons with Peripheral Neuropathy and High Fall Risk – the walk2Wellness Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.02.20166231
DO 10.1101/2020.08.02.20166231
A1 Oddsson, Lars IE
A1 Bisson, Teresa
A1 Cohen, Helen S
A1 Jacobs, Laura
A1 Khoshnoodi, Mohammad
A1 Kung, Doris
A1 Lipsitz, Lewis A
A1 Manor, Brad
A1 McCracken, Patricia
A1 Rumsey, Yvonne
A1 Wrisley, Diane M
A1 Koehler-McNicholas, Sara R
YR 2020
UL http://medrxiv.org/content/early/2020/08/04/2020.08.02.20166231.1.abstract
AB Background Patients with sensory peripheral neuropathy (PN) commonly present with gait and balance problems increasing their risk of falls. The multi-site walk2Wellness trial investigates effects of long-term, home-based daily use of a wearable lower limb sensory neuroprosthesis on gait function, balance, quality of life and fall rates in a cohort of PN patients. The device (Walkasins®, RxFunction Inc., MN, USA) is designed to replace lost nerve function related to foot pressure sensation by providing directional tactile cues around the ankle reflecting foot pressure measurements during standing and walking activities. We hypothesized that previously shown short-term in-clinic improvements in gait and balance would be sustained after 10 weeks of use.Methods Participants had a PN diagnosis with loss of plantar sensation associated with gait and balance problems, a Functional Gait Assessment (FGA) score <23 (cut-off for high fall risk), and ability to sense Leg Unit tactile stimuli. Clinical outcomes included FGA, Gait Speed, Timed Up&Go (TUG) and Four-Stage Balance Test. Patient-reported outcomes included Activities-Specific Balance Confidence (ABC) scale, Vestibular Disorders Activities of Daily Living Scale (VADL), PROMIS participation and satisfaction scores, pain rating, and falls. Evaluations were performed at baseline visit and after 2, 6, and 10 weeks. Subjects were not made aware of any changes in outcomes and no additional balance interventions were allowed.Results Forty-five participants of 52 enrolled across four sites completed all in-clinic assessments. FGA scores improved from 15.0 at baseline to 19.1 at 10 weeks (p<0.000001), normal and fast gait speed from 0.86m/s to 0.95m/s (p<0.00005) and 1.24m/s to 1.33m/s (p<0.002), respectively, and TUG from 13.8s to 12.5s (p<0.012). Four-Stage Balance Test did not improve significantly. Several patient-reported outcomes were in normal range at baseline and remained largely unchanged. Interestingly, while FGA scores improved similarly across the baseline range, subjects with baseline ABC scores lower than 67% (cut-off for high fall risk) showed an increase in their ABC scores (from 49.9% to 59.3%, p<0.01), whereas subjects with baseline ABC scores above 67% showed a decrease (from 76.6% to 71.8%, p<0.019). Subjects who reported falls in the prior six months (n=25) showed a decrease in the number of fall-risk factors (from 5.1 to 4.3, p<0.023) as well as a decrease in fall rate from 13.8 to 7.4 falls/1000 days (p<0.014). Four subjects in the pre-study non-faller group (n=20) fell during the 10 weeks of the study.Conclusion A wearable sensory neuroprosthesis may provide a new way to treat gait and balance problems and manage falls in high fall-risk patients with PN.Trial registration ClinicalTrials.gov (#NCT03538756)Competing Interest StatementMixed competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: LO is an inventor of the technology, Co-Founder of RxFunction, a shareholder in the company, serves on its Board of Directors and is an employee of the company. LJ is an employee of RxFunction and YR provides paid consulting services to RxFunction. The remaining authors received grant funding from RxFunction for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.Clinical TrialNCT03538756Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT03538756 Funding StatementThe walk2Wellness trial is completely funded by RxFunction. Sites have received funding from RxFunction to conduct research activities related to the trial.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human subject testing was approved according to the Declaration of Helsinki by Advarra IRB (formerly Quorum Review IRB), serving as the Institutional Review Board (IRB) of record for three of the participating sites under the study protocol. The three sites include Baylor College of Medicine, Houston, TX; Hebrew SeniorLife, a Harvard Medical School Affiliate, Boston, MA; and M Health Fairview, Minneapolis, MN. The IRB Subcommittee, the Subcommittee on Research Safety, and the Research and Development Committee of the Minneapolis VA Health Care System (MVAHCS) also approved the trial. The study is registered on ClinicalTrials.gov (#NCT03538756).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatasets from the current study are available upon request. The raw data supporting the conclusions of this article will be made available to qualified researchers, without undue reservation.